Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCδ gene

Journal of Pineal Research

Volumn 58, Issue 1, 2015, Pages 86-106

  Nguyen, Xuan Khanh Thi ^a   Lee, Jaehwi ^b   Shin, Eun Joo ^a   Dang, Duy Khanh ^a   Jeong, Ji Hoon ^b   Nguyen, Thuy Ty Lan ^a   Nam, Yunsung ^a   Cho, Hyun Jong ^a   Lee, Jae Chul ^a   Park, Dae Hun ^c   Jang, Choon Gon ^d   Hong, Jau Shyong ^e   Nabeshima, Toshitaka ^f,g   Kim, Hyoung Chun ^a  

^a Kangwon National University   (South Korea)

^b Chung Ang University   (South Korea)

^c Dongshin University   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^f MEIJO UNIVERSITY   (Japan)

^g Japanese Drug Organization of Appropriate Use and Research   (Japan)

Author keywords

dopamine; liposomal melatonin; methamphetamine; mitochondria; oxidative stress; pro apoptosis; protein kinase C

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CASPASE 3; CYTOCHROME C; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; MALONALDEHYDE; MELATONIN; METHAMPHETAMINE; PROTEIN BCL XL; PROTEIN KINASE C DELTA; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; ANTIOXIDANTS; DOPAMINE UPTAKE INHIBITORS; LIPOSOMES; PRKCD PROTEIN, MOUSE; PROTEIN KINASE C-DELTA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC DEGENERATION; DOPAMINERGIC SYSTEM; ELECTRON MICROSCOPY; ENZYME ACTIVITY; GENE TRANSLOCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTHERMIA; IMMUNOCYTOCHEMISTRY; LIPID PEROXIDATION; LIPOSOMAL DELIVERY; LIQUID CHROMATOGRAPHY; LOCOMOTION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; SYNAPTOSOME; TANDEM MASS SPECTROMETRY; TURNOVER TIME; ANIMALS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MICE; MICE, KNOCKOUT; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; LIPOSOMES; MELATONIN; METHAMPHETAMINE; MICE; MICE, KNOCKOUT; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; PROTEIN KINASE C-DELTA;

EID: 84919674973     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12195     Document Type: Article

References (75)

1. Cadet JL, Krasnova IN,. Molecular bases of methamphetamine-induced neurodegeneration. Int Rev Neurobiol 2009; 88: 101-119.
2. Granado N, Lastres-Becker I, Ares-Santos S, et al. Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia 2011; 59: 1850-1863.
3. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54: 1916-1921.
4. Shin EJ, Shin SW, Nguyen TT, et al. Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cdelta gene. Mol Neurobiol 2014; 49: 1400-1421.
5. Wu CW, Ping YH, Yen JC, et al. Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis. Toxicol Appl Pharmacol 2007; 220: 243-251.
6. Chin MH, Qian WJ, Wang H, et al. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J Proteome Res 2008; 7: 666-677.
7. Nishizuka Y,. Studies and perspectives of protein kinase C. Science 1986; 233: 305-312.
8. Nishizuka Y,. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607-614.
9. Basu A, Pal D,. Two faces of protein kinase Cdelta: The contrasting roles of PKCdelta in cell survival and cell death. ScientificWorldJournal 2010; 10: 2272-2284.
10. Kanthasamy AG, Kitazawa M, Kanthasamy A, et al. Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis. Antioxid Redox Signal 2003; 5: 609-620.
11. Shin EJ, Duong CX, Nguyen TX, et al. PKCdelta inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment. Neurochem Int 2011; 59: 39-50.
12. Shin EJ, Duong CX, Nguyen XK, et al. Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cdelta. Behav Brain Res 2012; 232: 98-113.
13. Zhang HM, Zhang Y,. Melatonin: A well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res 2014; 57: 131-146.
14. Tocharus J, Khonthun C, Chongthammakun S, et al. Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines. J Pineal Res 2010; 48: 347-352.
15. Juan WS, Huang SY, Chang CC, et al. Melatonin improves neuroplasticity by upregulating the growth-associated protein-43 (GAP-43) and NMDAR postsynaptic density-95 (PSD-95) proteins in cultured neurons exposed to glutamate excitotoxicity and in rats subjected to transient focal cerebral ischemia even during a long-term recovery period. J Pineal Res 2014; 56: 213-223.
16. Hardeland R,. Melatonin and theories of aging: A critical appraisal of melatonin's role in antiaging mechanisms. J Pineal Res 2013; 55: 325-356.
17. Niu S, Li F, Tan DX, et al. Analysis of N1-acetyl-N2-formyl-5-methoxykynuramine/N1-acetyl-5-kynuramine formation from melatonin in mice. J Pineal Res 2010; 49: 106-114.
18. Ressmyer AR, Mayo JC, Zelosko V, et al. Antioxidant properties of the melatonin metabolite N1-acetyl-5-kynuramine (AMK): Scavenging of free radicals and prevention of protein destruction. Redox Rep 2003; 8: 205-213.
19. Schaefer M, Hardeland R,. The melatonin metabolite N-acetyl-5-kynuramine is a potent singlet oxygen scavenger. J Pineal Res 2009; 46: 49-52.
20. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites. AFMK and AMK. J Pineal Res 2013; 54: 245-257.
21. Jou MJ, Peng TI, Reiter RJ, et al. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 2004; 37: 55-70.
22. Tan DX, Manchester LC, Liu X, et al. Mitochondria and chloroplasts as the original sites of melatonin synthesis: A hypothesis related to melatonin's primary function and evolution in eukaryotes. J Pineal Res 2013; 54: 127-138.
23. Parameyong A, Charngkaew K, Govitrapong P, et al. Melatonin attenuates methamphetamine-induced disturbances in mitochondrial dynamics and degeneration in neuroblastoma SH-SY5Y cells. J Pineal Res 2013; 55: 313-323.
24. Wisessmith W, Phansuwan-Pujito P, Govitrapong P, et al. Melatonin reduces induction of Bax, caspase and cell death in methamphetamine-treated human neuroblastoma SH-SY5Y cultured cells. J Pineal Res 2009; 46: 433-440.
25. Jumnongprakhon P, Govitrapong P, Tocharus C, et al. Protective effect of melatonin on methamphetamine-induced apoptosis in glioma cell line. Neurotox Res 2014; 25: 286-294.
26. Hirata H, Asanuma M, Cadet JL,. Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain. Synapse 1998; 30: 150-155.
27. Itzhak Y, Martin JL, Ali SF,. Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1177-1183.
28. Yu L, Cherng CF, Chen C,. Melatonin in concentrated ethanol and ethanol alone attenuate methamphetamine-induced dopamine depletions in C57BL/6J mice. J Neural Transm 2002; 109: 1477-1490.
29. Menendez-Pelaez A, Reiter RJ,. Distribution of melatonin in mammalian tissues: The relative importance of nuclear versus cytosolic localization. J Pineal Res 1993; 15: 59-69.
30. Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39: 307-313.
31. Mallo C, Zaidan R, Galy G, et al. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 1990; 38: 297-301.
32. Demuro RL, Nafziger AN, Blask DE, et al. The absolute bioavailability of oral melatonin. J Clin Pharmacol 2000; 40: 781-784.
33. Ulrich AS,. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 2002; 22: 129-150.
34. Kirjavainen M, Monkkonen J, Saukkossari M, et al. Phospholipids affect stratum corneum lipid bilayer fluidity and drug partitioning into the bilayers. J Controlled Release 1999; 58: 207-214.
35. Malam Y, Loizidou M, Seifalian AM,. Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30: 592-599.
36. Torres-Farfan C, Seron-Ferre M, Dinet V, et al. Immunocytochemical demonstration of day/night changes of clock gene protein levels in the murine adrenal gland: Differences between melatonin-proficient (C3H) and melatonin-deficient (C57BL) mice. J Pineal Res 2006; 40: 64-70.
37. Uz T, Javaid JI, Manev H,. Circadian differences in behavioral sensitization to cocaine: Putative role of arylalkylamine N-acetyltransferase. Life Sci 2002; 70: 3069-3075.
38. Miyamoto A, Nakayama K, Imaki H, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature 2002; 416: 865-869.
39. Kocadagli T, Yilmaz C, Gokmen V,. Determination of melatonin and its isomer in foods by liquid chromatography tandem mass spectrometry. Food Chem 2014; 153: 151-156.
40. Tran HY, Shin EJ, Saito K, et al. Protective potential of IL-6 against trimethyltin-induced neurotoxicity in vivo. Free Radic Biol Med 2012; 52: 1159-1174.
41. Shin EJ, Jeong JH, Kim AY, et al. Protection against kainate neurotoxicity by ginsenosides: Attenuation of convulsive behavior, mitochondrial dysfunction, and oxidative stress. J Neurosci Res 2009; 87: 710-722.
42. Bruce-Keller AJ, Geddes JW, Knapp PE, et al. Anti-death properties of TNF against metabolic poisoning: Mitochondrial stabilization by MnSOD. J Neuroimmunol 1999; 93: 53-71.
43. Eyerman DJ, Yamamoto BK,. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem 2007; 103: 1219-1227.
44. Wang Q, Shin EJ, Nguyen XK, et al. Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J Neuroinflammation 2012; 9: 124.
45. West MJ,. New stereological methods for counting neurons. Neurobiol Aging 1993; 14: 275-285.
46. Jung BD, Shin EJ, Nguyen XK, et al. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 2010; 56: 229-244.
47. Nakajima A, Yamada K, Nagai T, et al. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 2004; 24: 2212-2225.
48. Franklin KBJ, Paxinos G,. The Mouse Brain in Stereotaxic Coordinates, 3rd edn, Academic Press, San Diego, CA, 2008.
49. Liedtke CM, Cole T,. Antisense oligodeoxynucleotide to PKC-delta blocks alpha 1-adrenergic activation of Na-K-2Cl cotransport. Am J Physiol 1997; 273: C1632-C1640.
50. Shin EJ, Jeong JH, Bing G, et al. Kainate-induced mitochondrial oxidative stress contributes to hippocampal degeneration in senescence-accelerated mice. Cell Signal 2008; 20: 645-658.
51. Mattson MP,. Parkinson's disease: Don't mess with calcium. J Clin Invest 2012; 122: 1195-1198.
52. Deng X, Cadet JL,. Methamphetamine-induced apoptosis is attenuated in the striata of copper-zinc superoxide dismutase transgenic mice. Brain Res Mol Brain Res 2000; 83: 121-124.
53. Zhu JP, Xu W, Angulo JA,. Methamphetamine-induced cell death: Selective vulnerability in neuronal subpopulations of the striatum in mice. Neuroscience 2006; 140: 607-622.
54. Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996; 2: 699-703.
55. Fumagalli F, Gainetdinov RR, Valenzano KJ, et al. Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. J Neurosci 1998; 18: 4861-4869.
56. Roseboom PH, Coon SL, Baler R, et al. Melatonin synthesis: Analysis of the more than 150-fold nocturnal increase in serotonin N-acetyltransferase messenger ribonucleic acid in the rat pineal gland. Endocrinology 1996; 137: 3033-3045.
57. Roseboom PH, Namboodiri MA, Zimonjic DB, et al. Natural melatonin 'knockdown' in C57BL/6J mice: Rare mechanism truncates serotonin N-acetyltransferase. Brain Res Mol Brain Res 1998; 63: 189-197.
58. Ebihara S, Marks T, Hudson DJ, et al. Genetic control of melatonin synthesis in the pineal gland of the mouse. Science 1986; 231: 491-493.
59. Goto M, Oshima I, Tomita T, et al. Melatonin content of the pineal gland in different mouse strains. J Pineal Res 1989; 7: 195-204.
60. Vivien-Roels B, Malan A, Rettori MC, et al. Daily variations in pineal melatonin concentrations in inbred and outbred mice. J Biol Rhythms 1998; 13: 403-409.
61. Goto M, Oshima I, Hasegawa M, et al. The locus controlling pineal serotonin N-acetyltransferase activity (Nat-2) is located on mouse chromosome 11. Brain Res Mol Brain Res 1994; 21: 349-354.
62. Gibb JW, Bush L, Hanson GR,. Exacerbation of methamphetamine-induced neurochemical deficits by melatonin. J Pharmacol Exp Ther 1997; 283: 630-635.
63. Imam SZ, El-Yazal J, Newport GD, et al. Methamphetamine-induced dopaminergic neurotoxicity: Role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann N Y Acad Sci 2001; 939: 366-380.
64. Kaewsuk S, Sae-Ung K, Phansuwan-Pujito P, et al. Melatonin attenuates methamphetamine-induced reduction of tyrosine hydroxylase, synaptophysin and growth-associated protein-43 levels in the neonatal rat brain. Neurochem Int 2009; 55: 397-405.
65. Dubey V, Mishra D, Jain NK,. Melatonin loaded ethanolic liposomes: Physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm 2007; 67: 398-405.
66. Cubells JF, Rayport S, Rajendran G, et al. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 1994; 14: 2260-2271.
67. Riddle EL, Fleckenstein AE, Hanson GR,. Role of monoamine transporters in mediating psychostimulant effects. AAPS J 2005; 7: E847-E851.
68. Fleckenstein AE, Metzger RR, Wilkins DG, et al. Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 1997; 282: 834-838.
69. Vergo S, Johansen JL, Leist M, et al. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res 2007; 1185: 18-32.
70. Nicholls DG,. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim Biophys Acta 2009; 1787: 1416-1424.
71. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619-628.
72. Nomura M, Shimizu S, Sugiyama T, et al. 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 2003; 278: 2058-2065.
73. Suwanjang W, Phansuwan-Pujito P, Govitrapong P, et al. The protective effect of melatonin on methamphetamine-induced calpain-dependent death pathway in human neuroblastoma SH-SY5Y cultured cells. J Pineal Res 2010; 48: 94-101.
74. Miyazaki I, Asanuma M, Kikkawa Y, et al. Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity. Glia 2011; 59: 435-451.
75. Zhang W, Shin EJ, Wang T, et al. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J 2006; 20: 2496-2511.